Rheumatology
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Ixifi (infliximab qbtx) as a biosimilar medication
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Ixifi (infliximab qbtx) as a biosimilar medication
Biosimilars
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Ixifi (infliximab qbtx) as a biosimilar to Remicade (infliximab; Janssen) for all the same indications.
The indications include treatment of: ;
- rheumatoid arthritis
- Crohn's disease in adults and children
- ulcerative colitis
- ankylosing spondylitis
- psoriatic arthritis
- psoriasis
Biosimilars have equivalent efficacy to their bio-originals and do not have a worse safety profile.
They are significantly cheaper than the bio-originals.
People spend 40 hours or more at work. Therefore, psychologists advise that the workspace should be organized in a way that makes a person feel as comfortable as possible. The workspace can not only increase productivity but also affect health, Medical Express reports.Book a visit — we will pick a convenient time.